Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05351749 · ClinicalTrials.gov registry record · NA

Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use

A NA study of Atrial Fibrillation and Pulmonary Embolism, sponsored by University of Michigan.

Active
Registry status
NA
Development phase
306
Enrollment target
1
Study location

NCT05351749: Active NA study of Atrial Fibrillation and Pulmonary Embolism, sponsored by University of Michigan.

NCT05351749 is a NA study of Atrial Fibrillation and Pulmonary Embolism that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 306 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05351749, a NA study of Atrial Fibrillation and Pulmonary Embolism, is active but no longer recruiting, sponsored by University of Michigan.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
306 participants
Enrollment target
1
Study location

Study Summary

The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral option is associated with a higher rate of prescription changes for initial-prescription alerts that are directed to the prescriber at the time of initial-prescribing errors. Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high risk medications, including anticoagulants

Primary Outcome

Existing-prescription notification conditions = Prescriber notification \& Pharmacist notification The number of notifications (in the existing-prescription notification conditions) that are addressed within 7 days/ total number of notifications

Interventions

  • BEHAVIORAL New-prescription Alert
  • BEHAVIORAL New-prescription Alert with referral option
  • BEHAVIORAL Existing-prescription notification to prescriber
  • BEHAVIORAL Existing-prescription notification to pharmacist

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 306 participants
Start Date 2022-08-01
Est. Completion 2026-01
Phase NA
University of Michigan

1,327 total trials

What the registry record for NCT05351749 still lists

NCT05351749 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 4 interventions - of which New-prescription Alert is the first listed.

NCT05351749 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT05351749 about?

NCT05351749 is a clinical study titled "Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use". The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral opti...

What is the current status of trial NCT05351749?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 306 participants. The study started on 2022-08-01. Estimated completion is 2026-01.

What conditions does trial NCT05351749 study?

This clinical trial studies the following conditions: Atrial Fibrillation, Pulmonary Embolism, Venous Thromboembolism.

What interventions are being tested in trial NCT05351749?

The interventions under investigation include: New-prescription Alert (BEHAVIORAL), New-prescription Alert with referral option (BEHAVIORAL), Existing-prescription notification to prescriber (BEHAVIORAL), Existing-prescription notification to pharmacist (BEHAVIORAL).

Who is sponsoring clinical trial NCT05351749?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05351749 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05351749's enrollment target sits among peer trials

306 81st of 202 higher than 122 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05078970 · 306 participants · NA

    Advancing Suicide Intervention Strategies for Teens During High Risk Periods

  • NCT05843695 · 306 participants · NA

    Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety

  • NCT06057337 · 306 participants · NA

    Families With Pride ("Familias Con Orgullo").

  • NCT06498635 · 306 participants · Phase 3

    Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05351749, the US trial registry maintained by the National Library of Medicine. NCT05351749 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.